retatrutide peptide brand name Triple Agonist (GLP-1/GIP/GCG) Demand for Unapproved Weight-Loss Drug

Potential Benefits & Side Effects Observations from clinical trials and FDA-approved use

1 providers serving Lee's Summit offer telehealth GLP-1 consultations

Nesfatin is cleaved into three different forms: nesfatin-1, nesfatin-2, and nesfatin-3 226

Harder because: you lack the deep receptor adaptation that higher-dose tirzepatide users have, meaning the GLP-1 and GIP components of retatrutide may hit you harder than expected at relatively low doses

NIHR Be Part of Research (bepartofresearch.nihr.ac.uk) is the recommended starting point for patients interested in joining a trial

Treatment stage What may be common What deserves attention Week 1 Nausea, fullness, reduced appetite, bloating, indigestion, diarrhea, constipation, fatigue Repeated vomiting, severe pain, inability to stay hydrated Weeks 2 to 4 Early symptoms may settle, persist, or fluctuate Symptoms interfering with eating, drinking, or daily function Weeks 5 to 8 Symptoms may reappear after clinician-directed dose escalation A significant return or worsening of gastrointestinal symptoms Months 2 to 3 Some patients tolerate treatment more comfortably